Two-drug combination for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two new drugs together: Actimab-A (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people whose glioblastoma has returned after initial treatment, and the goal is to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain cancer called glioblastoma (or a related type called gliosarcoma) that has come back after initial treatment. Your tumor must not have a specific genetic marker (IDH wild type).
- Your cancer must show measurable growth on scans, and you must be in your first or second relapse.
- You must have already had radiation therapy to your brain as part of your first treatment, and at least 6 months must have passed if you received a high dose.
- You cannot have had certain immunotherapy drugs (like PD-1, PD-L1, or CTLA-4 inhibitors) before. You also cannot have had bevacizumab within the last 6 weeks.
- You must be 18 years or older, able to perform daily activities with some help (ECOG 0-2), and have adequate organ function (kidney, liver, and blood counts).
- You cannot be pregnant, and if you can have children, you must agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a new combination of two drugs, entacapone and bevacizumab, for people whose glioblastoma (a type of brain tumor) has returned after initial treatment. The goal is to see if this combination can help control the tumor and improve outcomes.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.